141 related articles for article (PubMed ID: 1789205)
1. ICI D1694, an inhibitor of thymidylate synthase for clinical study.
Jackman AL; Jodrell DI; Gibson W; Stephens TC
Adv Exp Med Biol; 1991; 309A():19-23. PubMed ID: 1789205
[TBL] [Abstract][Full Text] [Related]
2. ICI D1694, a quinazoline antifolate thymidylate synthase inhibitor that is a potent inhibitor of L1210 tumor cell growth in vitro and in vivo: a new agent for clinical study.
Jackman AL; Taylor GA; Gibson W; Kimbell R; Brown M; Calvert AH; Judson IR; Hughes LR
Cancer Res; 1991 Oct; 51(20):5579-86. PubMed ID: 1913676
[TBL] [Abstract][Full Text] [Related]
3. Use of murine L5178Y lymphoma thymidine kinase mutants for in vitro and in vivo antitumour efficacy evaluation of novel thymidylate synthase inhibitors.
Stephens TC; Smith MN; Waterman SE; McCloskey ML; Jackman AL; Boyle FT
Adv Exp Med Biol; 1993; 338():589-92. PubMed ID: 8304186
[No Abstract] [Full Text] [Related]
4. The role of the reduced-folate carrier and metabolism to intracellular polyglutamates for the activity of ICI D1694.
Jackman AL; Gibson W; Brown M; Kimbell R; Boyle FT
Adv Exp Med Biol; 1993; 339():265-76. PubMed ID: 7513935
[TBL] [Abstract][Full Text] [Related]
5. Thymidylate synthase inhibitors: the in vitro activity of a series of heterocyclic benzoyl ring modified 2-desamino-2-methyl-N10-substituted-5,8-dideazafolates.
Jackman AL; Marsham PR; Moran RG; Kimbell R; O'Connor BM; Hughes LR; Calvert AH
Adv Enzyme Regul; 1991; 31():13-27. PubMed ID: 1877386
[TBL] [Abstract][Full Text] [Related]
6. The duration of the inhibition of thymidylate synthase in intact L1210 cells exposed to two different classes of quinazoline analogues.
Kimbell R; Jackman AL; Boyle FT; Hardcastle A; Aherne W
Adv Exp Med Biol; 1993; 338():597-600. PubMed ID: 8304189
[No Abstract] [Full Text] [Related]
7. The measurement of polyglutamate metabolites of the thymidylate synthase inhibitor, ICI D1694, in mouse and human cultured cells.
Gibson W; Bisset GM; Marsham PR; Kelland LR; Judson IR; Jackman AL
Biochem Pharmacol; 1993 Feb; 45(4):863-9. PubMed ID: 7680860
[TBL] [Abstract][Full Text] [Related]
8. Kinetic characteristics of ICI D1694: a quinazoline antifolate which inhibits thymidylate synthase.
Ward WH; Kimbell R; Jackman AL
Biochem Pharmacol; 1992 May; 43(9):2029-31. PubMed ID: 1596289
[TBL] [Abstract][Full Text] [Related]
9. 5,10-Dideazatetrahydrofolic acid reduces toxicity and deoxyadenosine triphosphate pool, expansion in cultured L1210 cells treated with inhibitors of thymidylate synthase.
Chong LK; Tattersall MH
Biochem Pharmacol; 1995 Mar; 49(6):819-27. PubMed ID: 7702640
[TBL] [Abstract][Full Text] [Related]
10. Susceptibility of Plasmodium falciparum to a combination of thymidine and ICI D1694, a quinazoline antifolate directed at thymidylate synthase.
Rathod PK; Reshmi S
Antimicrob Agents Chemother; 1994 Mar; 38(3):476-80. PubMed ID: 8203840
[TBL] [Abstract][Full Text] [Related]
11. Quinazoline antifolates inhibiting thymidylate synthase: synthesis of gamma-linked peptide and amide analogues of 2-desamino-2-methyl-N10-propargyl- 5,8-dideazafolic acid (ICI 198583).
Bavetsias V; Jackman AL; Thornton TJ; Pawelczak K; Boyle FT; Bisset GM
Adv Exp Med Biol; 1993; 338():593-6. PubMed ID: 8304188
[No Abstract] [Full Text] [Related]
12. The thymidylate synthase inhibitor, ICI D1694, overcomes translational detainment of the enzyme.
Keyomarsi K; Samet J; Molnar G; Pardee AB
J Biol Chem; 1993 Jul; 268(20):15142-9. PubMed ID: 8325888
[TBL] [Abstract][Full Text] [Related]
13. Antitumor activity of antifolate inhibitors of thymidylate and purine synthesis in human soft tissue sarcoma cell lines with intrinsic resistance to methotrexate.
Li WW; Tong WP; Bertino JR
Clin Cancer Res; 1995 Jun; 1(6):631-6. PubMed ID: 9816025
[TBL] [Abstract][Full Text] [Related]
14. The toxicity of ICI D1694 in man and mouse.
Clarke SJ; Jackman AL; Judson IR
Adv Exp Med Biol; 1993; 338():601-4. PubMed ID: 8304190
[No Abstract] [Full Text] [Related]
15. Biochemical effects of folate-based inhibitors of thymidylate synthase in MGH-U1 cells.
Mitrovski B; Pressacco J; Mandelbaum S; Erlichman C
Cancer Chemother Pharmacol; 1994; 35(2):109-14. PubMed ID: 7987985
[TBL] [Abstract][Full Text] [Related]
16. The biochemical pharmacology of the thymidylate synthase inhibitor, 2-desamino-2-methyl-N10-propargyl-5,8-dideazafolic acid (ICI 198583).
Jackman AL; Newell DR; Gibson W; Jodrell DI; Taylor GA; Bishop JA; Hughes LR; Calvert AH
Biochem Pharmacol; 1991 Oct; 42(10):1885-95. PubMed ID: 1741766
[TBL] [Abstract][Full Text] [Related]
17. Cellular heterogeneity in DNA damage and growth inhibition induced by ICI D1694, thymidylate synthase inhibitor, using single cell assays.
Schöber C; Gibbs JF; Yin MB; Slocum HK; Rustum YM
Biochem Pharmacol; 1994 Aug; 48(5):997-1002. PubMed ID: 8093112
[TBL] [Abstract][Full Text] [Related]
18. ICI D1694 and idoxuridine: a synergistic antitumor combination.
Pressacco J; Hedley DW; Erlichman C
Cancer Res; 1994 Jul; 54(14):3772-8. PubMed ID: 8033097
[TBL] [Abstract][Full Text] [Related]
19. Modulation of target enzyme associated with the action of antifolates.
Rustum YM; Cao S; Yin MB
Adv Enzyme Regul; 1994; 34():57-70. PubMed ID: 7942285
[TBL] [Abstract][Full Text] [Related]
20. Combination studies with 3'-azido-3'-deoxythymidine (AZT) plus ICI D1694. Cytotoxic and biochemical effects.
Pressacco J; Erlichman C
Biochem Pharmacol; 1993 Dec; 46(11):1989-97. PubMed ID: 8267649
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
